Skip to content

Evaluation of Spinal Cord Stimulation Pulse Rate On Clinical Outcomes

Evaluation of Stimulation Pulse Rate on Clinical Outcomes in Patients Whose Pain is Controlled by 10KHz Frequency - a Feasibility Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02549183
Acronym
PROCO
Enrollment
22
Registered
2015-09-15
Start date
2015-06-01
Completion date
2017-07-13
Last updated
2020-12-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Back Pain, Neuralgia

Keywords

Spinal Cord Stimulation

Brief summary

Clinical study to estimate the optimal frequency for stimulation of the spinal cord to achieve relief from back pain.

Detailed description

This is a feasibility study to identify the optimal frequency for stimulation of the spinal cord to achieve maximum reduction in neuropathic back pain as measured by average Numerical rating Scale. Twenty patients who suffer from back more than leg pain will be recruited into the study once they have satisfactory pain relief from both low and high frequency stimulations. Each patient will then receive stimulation at four different frequencies for 2-3 weeks in a random and blinded order. Their pain scores and function will be assessed using a variety of different tools. The data will then be used to estimate the optimal frequency.

Interventions

DEVICEBoston Scientific PRECISION Spinal Cord Stimulator System

Spinal cord stimulation randomly programmed to KHz frequencies; A, B, C and D Kilo Hertz.

Sponsors

North Bristol NHS Trust
CollaboratorOTHER
Mid and South Essex NHS Foundation Trust
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Complaint of persistent or recurrent low back pain, with or without equal or lesser leg pain, for at least 90 days prior to Screen. 2. Received at least 90 days of documented pain management care to address the primary pain complaint, prior to Screening (e.g. medication, physical therapy.) 3. No back surgery within 6 months prior to Screening. 4. Average low back pain intensity, during the position/activity, which routinely causes worst pain, of 5 or greater on a 0-10 numerical rating scale during Baseline period based on eDiary. 5. If taking prescription opioids for primary chronic pain complaint (low back and/or leg pain), must have been on a stable prescription (same drug(s) and dose(s)) 30 days prior to Screening to a total of less than 180 mg Oral Morphine equivalent 6. Willing and able to comply with all protocol-required procedures and assessments/evaluations (e.g. willing to comply with opioid prescription lock from the Baseline visit through End of Rate Randomization and protocol required stimulation parameter locks, complete daily eDiary). 7. 18 years of age or older when written informed consent is obtained. 8. If female of childbearing potential: not pregnant, as evidenced by a negative pregnancy test at Screening. 9. Subject signed a valid, IRB-approved informed consent form (ICF) provided in English. 10. Baseline Oswestry Disability Index score ≥ 20 and ≤ 80. 11. Received at least 30 per cent reduction in NRS of average low back pain intensity from Baseline during the end of Post Implant HF10 Sweet-Spot Search as recorded in the eDiary.

Exclusion criteria

1. Average worst leg pain intensity is greater than average worst low back pain intensity as reported during Baseline period based on eDiary. 2. Radiographic evidence of spinal instability requiring fusion. 3. Primary pain complaint of vascular origin (e.g. peripheral vascular disease). 4. Spinal pain secondary to neoplasm, infection, autoimmune disorder with spinal involvement, or a spinal metabolic disorder. 5. Any pain-related diagnosis or medical/psychological condition that, in the clinician's best judgment might confound reporting of study outcomes (e.g. pelvic pain, angina pain, chronic migraine. 6. Participating (or intends to participate) in another clinical study. 7. Terminal illness with anticipated survival 1 year. 8. Current condition associated with risk of immunocompromised that might increase risk of infection during study duration. 9. Currently on any anticoagulant medications that cannot be discontinued during perioperative period. 10. Are pregnant/lactating or not using adequate birth control. 11. Have untreated major psychiatric comorbidity, serious drug related behaviour issues.

Design outcomes

Primary

MeasureTime frameDescription
Back pain reliefThree monthsMean reported pain on Numerical Rating Scale (NRS)

Secondary

MeasureTime frameDescription
Leg pain relief3-6 monthsMean reported pain on Numerical Rating Scale (NRS)
Patient global impression of change at end of Long-Term Follow-up6-9 monthsQuestionnaire
Change in quality of life (EQ-5D) from Baseline Visit to end of Long-Term Follow-up6-9 monthsQuestionnaire
Change in activities of Daily Living related to back pain disability from Baseline visit to end of Long-Term Follow-up6-9 monthsQuestionnaire

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026